Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.

Cost of Revenue Trends: Gilead Sciences, Inc. vs. Intra-Cellular Therapies, Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Gilead Sciences, Inc. has consistently demonstrated a robust cost of revenue, peaking in 2021 with a 38% increase from 2014. This reflects Gilead's strategic investments in production and distribution, ensuring their market dominance. In contrast, Intra-Cellular Therapies, Inc., a smaller player, has shown a remarkable growth trajectory, with a staggering 1,500% increase in cost of revenue from 2015 to 2023. This surge underscores their aggressive expansion and scaling efforts. While Gilead's cost of revenue remains significantly higher, Intra-Cellular's rapid growth highlights its potential in the competitive landscape. These insights provide a window into the operational strategies of these companies, offering valuable perspectives for potential investors.